Repligen Corporation (RGEN)

167,86 -3,42 (-2,00%) Börsenschluss: 04:00PM EDT

Repligen Corporation

Building 1
Suite 100 41 Seyon Street
Waltham, MA 02453
United States
781 250 0111
https://www.repligen.com

Sektor(en): Healthcare
Branche: Medical Instruments & Supplies
Vollzeitmitarbeiter: 1.783

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Anthony J. Hunt	CEO & Director	885k	N/A	1964
Mr. Olivier Loeillot	President & Chief Commercial Officer	1,49M	N/A	1970
Mr. Jason K. Garland	CFO & Chief Compliance Officer	282,99k	N/A	1974
Mr. James R. Bylund	Chief Operating Officer	472,18k	N/A	1964
Ms. Christine Gebski	Senior Vice President of Filtration & Chromatography	396,09k	N/A	1968
Mr. Ralf Kuriyel	Senior Vice President of Research & Development	401,74k	N/A	1958
Mr. Keith Lee Robinson	Chief Information Officer	N/A	N/A	N/A
Ms. Sondra S. Newman	Global Head of Investor Relations	N/A	N/A	N/A
Ms. Kimberly A. Cornwell	General Counsel & Global Head of Legal	N/A	N/A	N/A
Dr. Jaime M. Humara Ph.D.	Senior Vice President of Global Marketing	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Repligen Corporations ISS Governance QualityScore, Stand 1. April 2024, lautet 2. Die grundlegenden Scores sind Audit: 5, Vorstand: 3, Shareholderrechte: 1, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.